Olga Lenčová-Popelová

发表

Proteomic investigation of embryonic rat heart-derived H9c2 cell line sheds new light on the molecular phenotype of the popular cell model.

M. Štěrba, J. Stulík, M. Link, 2015, Experimental cell research.

Experimental determination of diagnostic window of cardiac troponins in the development of chronic anthracycline cardiotoxicity and estimation of its predictive value.

M. Štěrba, F. Simko, M. Adamcová, 2015, International journal of cardiology.

Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity

N. Váňová, J. Chládek, M. Štěrba, 2021, Scientific Reports.

Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity

M. Štěrba, J. Kubeš, M. Adamcová, 2020, The Journal of Pharmacology and Experimental Therapeutics.

Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation

A. Lyon, M. Štěrba, J. Kubeš, 2021, Circulation. Heart failure.

Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo

D. Richardson, M. Muller, K. Vávrová, 2015 .

Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.

M. Štěrba, M. Adamcová, J. Vávrová, 2013, Toxicology.

Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity on a rabbit model in vivo.

N. Váňová, M. Štěrba, J. Kubeš, 2021, Clinical science.

Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.

J. Chládek, M. Štěrba, M. Adamcová, 2016, Journal of molecular and cellular cardiology.

In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline.

M. Štěrba, J. Kubeš, M. Adamcová, 2019, Clinical science.

Molecular Remodeling of Left and Right Ventricular Myocardium in Chronic Anthracycline Cardiotoxicity and Post-Treatment Follow Up

M. Štěrba, M. Adamcová, T. Šimůnek, 2014, PloS one.

Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?

M. Štěrba, J. Bureš, M. Adamcová, 2016, Toxicology.

Cardiac miRNA expression during the development of chronic anthracycline-induced cardiomyopathy using an experimental rabbit model

M. Štěrba, M. Adamcová, Y. Mazurová, 2024, Frontiers in pharmacology.

Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage

Lenka Applová, M. Štěrba, J. Roh, 2024, Toxicological sciences : an official journal of the Society of Toxicology.

Characterization of a new model of chemotherapy-induced heart failure with reduced ejection fraction and nephrotic syndrome in Ren-2 transgenic rats

M. Štěrba, J. Imig, Y. Mazurová, 2024, Hypertension research : official journal of the Japanese Society of Hypertension.